Group 1 - The company Heng Rui Medicine (600276.SH) has signed an exclusive licensing agreement with Hansoh Pharmaceutical Group Co., Ltd. to license its SHR6508 project [1] - SHR6508 is a novel calcium-sensing receptor allosteric modulator intended for the treatment of secondary hyperparathyroidism in adult patients undergoing hemodialysis, currently in Phase III clinical trials [1] - The company’s paricalcitol soft capsule product is expected to be approved for market launch by the National Medical Products Administration in November 2025 [1] Group 2 - Hansoh Pharmaceutical and its subsidiary, Jiangsu Hengrui Pharmaceutical Group Co., Ltd., are controlled by the spouse of the company's actual controller and chairman, Sun Piaoyang, making them related parties under listing rules [2] - Hansoh Pharmaceutical is a leading innovation-driven pharmaceutical company in China, focusing on major disease treatment areas such as oncology, anti-infection, central nervous system, metabolism, and autoimmune diseases [2]

智通财经APP讯，恒瑞医药(600276.SH)公告，公司与翰森制药集团有限公司("翰森制药")签署《独家许 可协议》，将公司SHR6508项目有偿许可给翰森制药;公司子公司成都盛迪医药有限公司("成都盛迪")与 翰森制药子公司江苏豪森药业集团有限公司("豪森药业")签署《商业化服务框架协议》，委托豪森药业 为公司帕立骨化醇软胶囊产品提供非独家商业化服务。 公告显示，翰森制药、豪森药业由公司实际控制人、董事长孙飘扬先生的配偶控制，根据上市规则规定 属于公司的关联方。翰森制药是中国领先的创新驱动型制药企业，下属豪森药业等子公司，重点关注抗 肿瘤、抗感染、中枢神经系统、代谢及自身免疫等重大疾病治疗领域。 据公告所示，SHR6508是一种新型钙敏感受体变构调节剂，拟用于治疗需接受血液透析的慢性肾脏病成 年患者的继发性甲状旁腺功能亢进症，目前正在进行Ⅲ期临床试验研究。钙敏感受体通过释放控制血液 钙水平的甲状旁腺激素(PTH)来监测并调控钙水平。由于对钙离子的敏感性增强，SHR6508给药后可减 少继发性甲状旁腺功能亢进症血液透析患者的PTH分泌。帕立骨化醇是一种合成的维生素D类似物，通 过与维生素D受体结合抑制甲状旁 ...